deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT01758588

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Sponsor: Merck Sharp & Dohme LLC

Conditions Myelofibrosis
Interventions Peginterferon alfa-2a
Updated 12 times since 2017 Last updated: Jun 28, 2018 Started: Jan 31, 2013 Primary completion: Jun 30, 2017 Completion: Jun 30, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This study was suspended due to insufficient subject accrual.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Myelofibrosis trials with similar outcome

Browse all Myelofibrosis trials

This PHASE2 trial investigates Myelofibrosis and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 12 recorded versions since 2013 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshotActive Not Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotTerminated~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshotTerminated~Aug 2018 – ~Jan 2021 · 29 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshotTerminated~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Jun 2022 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Dec 2021 — Jun 2022 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  3. Aug 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Aug 2018 [monthly]

    Terminated PHASE2

  5. Dec 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  6. Feb 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Weill Medical College of Cornell University
Data source: Weill Medical College of Cornell University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations